3 days popular7 days popular1 month popular3 months popular

Anti-fibrotic peptide shows early promise against interstitial lung disease

The results of preclinical studies by investigators at the Medical University of South Carolina (MUSC) reported in the April 2016 issue of Translational Research suggest that the M10 peptide could help protect against fibrotic damage in patients with systemic sclerosis, particularly in those who develop interstitial lung diseases (ILD), its deadliest complication.

The M10 Peptide
Lung tissue isolated from mice that received bleomycin is characterized by extensive infiltration of inflammatory cells, thickening of the alveolar walls, and multiple fibrotic lesions with excessive amounts of extracellular matrix proteins (left). Lung tissue from mice that received bleomycin and M10 treatment demonstrates significant reduction of cellular infiltrates, decreased thickness of alveolar septa, and reduced accumulation of extracellular matrix proteins (right).
Credit: Reproduced from Translational Research (http://www.translationalres.com/), Volume 170, April 2016, Pages 99-111, with permission from Elsevier.